Here are the Form 4 insider transactions from AgomAb Therapeutics NV (AGMB) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AGMB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AGMB filings page.
AgomAb Therapeutics NV (AGMB) director David R. Epstein purchased 14,980 common shares directly on November 13, 2026, across four reported transactions: 5,000 at $5.99, 20 at $6.00, 5,000 at $5.75 and 4,960 at $6.02 per share. No Rule 10b5-1 plan is reported.
AgomAb Therapeutics NV (AGMB) director David R. Epstein bought 15,000 common shares on November 5, 2026, across three reported purchases of 5,000 shares each. The reported prices were $6.81, $6.91 and $6.98 per share. The purchases were direct, and no Rule 10b5-1 plan is reported. Common shares may be represented by American Depositary Shares, each of which currently represents one common share.
AgomAb Therapeutics NV director David R. Epstein reported two direct purchases of 5,000 common shares each on October 21, 2026: 5,000 at $8.86 per share and 5,000 at $8.90 per share, totaling 10,000 shares. The footnote says the common shares may be represented by American Depositary Shares, each currently representing one common share.
AgomAb Therapeutics NV (AGMB) director David R. Epstein purchased 5,000 common shares at $8.90 per share on October 8, 2026. His reported direct holdings after the purchase were 15,000 shares. No Rule 10b5-1 plan is reported. The common shares may be represented by American Depositary Shares, each currently representing one common share.
AgomAb Therapeutics NV director David R. Epstein bought 5,000 common shares on October 5, 2026, at $8.57 per share, and 5,000 common shares on October 6, 2026, at $8.70 per share. Both purchases were reported as direct transactions, and no Rule 10b5-1 plan is reported. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.
AgomAb Therapeutics NV (AGMB) Chief Financial Officer Pierre Thadee Victor Kemula purchased 10,000 common shares directly on October 6, 2026, across three reported transactions: 3,000 at $8.67 per share, 5,000 at $8.57, and 2,000 at $8.54. No Rule 10b5-1 plan is reported. The common shares may be represented by American Depositary Shares, each currently representing one common share.
AgomAb Therapeutics NV (AGMB) Chief Executive Officer and director Tim Jasper Knotnerus reported two direct purchases of common shares: 6,000 at $8.48 on October 5, 2026, and 5,000 at $8.70 on October 6, 2026. No Rule 10b5-1 plan is reported for the purchases.
The report also lists 34,394 common shares held by TJK Life Sciences B.V. Knotnerus exercises voting and dispositive power over those shares and disclaims beneficial ownership for Section 16 purposes except to the extent of any pecuniary interest. Each American Depositary Share currently represents one common share.
Agomab Therapeutics NV (AGMB) reported that director Garcia Marino received a grant of 57,482 stock options on September 11, 2026. The options have an exercise price of $13.94 per common share, expire on January 15, 2036, and relate to common shares that may be represented by American Depositary Shares.
According to the vesting terms, 33% of the shares underlying this option vest on September 11, 2027, with the remaining options vesting in 24 equal monthly installments thereafter, subject to continued service. No Rule 10b5-1 trading plan is reported for this award.
AgomAb Therapeutics NV (AGMB) reported that director Naimish Patel received a grant of stock options on September 11, 2026. The award covers 56,328 options to purchase common shares at an exercise price of $13.94 per share, expiring on January 15, 2036.
Each option relates to one common share, which may be represented by an American Depositary Share. According to the vesting schedule, 33% of the shares underlying this option vest on September 11, 2027, with the remaining shares vesting in 24 equal monthly installments thereafter, subject to Mr. Patel’s continued service. The exercise price is shown in U.S. dollars based on a $1.1616 per EUR 1.00 exchange rate as of September 10, 2026, and no Rule 10b5-1 trading plan is reported for this grant.